TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

This trial is testing a combined treatment approach for people with inoperable liver cancer (hepatocellular carcinoma, or HCC) that needs to be "downstaged" — meaning shrunk enough to qualify for a liver transplant. The approach uses arterial chemotherapy (TACE), focused radiation (SBRT), and two immunotherapy drugs to try to shrink the tumor. **You may be eligible if...** - You are 18 or older with confirmed HCC that cannot be surgically removed - Your liver cancer has been diagnosed using standard imaging criteria - You are in good overall health (ECOG 0–1) and weigh over 30 kg - You are being considered for liver transplant downstaging **You may NOT be eligible if...** - Your cancer has spread outside the liver (except in specific, limited circumstances) - Your liver function is too poor to tolerate the treatment - You have active autoimmune disease or are on immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.